↓ Skip to main content


Overview of attention for book
Cover of 'N-Acetylaspartate'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 A Brief Overview of N -Acetylaspartate and N -Acetylaspartylglutamate
  3. Altmetric Badge
    Chapter 2 Expression of N -Acetylaspartate and N -Acetylaspartylglutamate in the Nervous System
  4. Altmetric Badge
    Chapter 3 N -Acetylaspartate Metabolism in Neural Cells
  5. Altmetric Badge
    Chapter 4 Naa Synthesis and Functional Roles
  6. Altmetric Badge
    Chapter 5 Identity of the High-Affinity Sodium/Carboxylate Cotransporter NaC3 as the N -Acetyl-L-Aspartate Transporter
  7. Altmetric Badge
    Chapter 6 Canavan Disease: Studies on the Knockout Mouse
  8. Altmetric Badge
    Chapter 7 Functions Of N -Acetylaspartate and N -Acetylaspartylglutamate in Brain
  9. Altmetric Badge
    Chapter 8 Control of Brain Volume during Hypoosmolality and Hyperosmolality
  10. Altmetric Badge
    Chapter 9 Physiological Role of N -Acetylaspartate
  11. Altmetric Badge
    Chapter 10 Defective Myelin Lipid Synthesis as a Pathogenic Mechanism of Canavan Disease
  12. Altmetric Badge
    Chapter 11 Mutation Analysis of the Aspartoacylase Gene in Non-Jewish Patients with Canavan Disease
  13. Altmetric Badge
    Chapter 12 Does ASPA Gene Mutation in Canavan Disease Alter Oligodendrocyte Development?
  14. Altmetric Badge
    Chapter 13 Quantitation of NAA in the Brain by Magnetic Resonance Spectroscopy
  15. Altmetric Badge
    Chapter 14 N-Acetyl-L-Aspartate in Multiple Sclerosis
  16. Altmetric Badge
    Chapter 15 NAA and higher cognitive function in humans.
  17. Altmetric Badge
    Chapter 16 In Vivo NMR Measures of NAA and the Neurobiology of Schizophrenia
  18. Altmetric Badge
    Chapter 17 N -Acetylaspartate as a Marker of Neuronal Injury in Neurodegenerative Disease
  19. Altmetric Badge
    Chapter 18 Regulation of NAA-Synthesis in the Human Brain in Vivo: Canavan’s Disease, Alzheimer’s Disease and Schizophrenia
  20. Altmetric Badge
    Chapter 19 Magnetic Resonance Spectroscopy for Monitoring Neuronal Integrity in Amyotrophic Lateral Sclerosis
  21. Altmetric Badge
    Chapter 20 Hypoacetylaspartia: Clinical and Biochemical Follow-Up of a Patient
  22. Altmetric Badge
    Chapter 21 Cellular localization of NAAG.
  23. Altmetric Badge
    Chapter 22 Synthesis of N-acetylaspartyl-glutamate (NAAG) and N-acetylaspartate (NAA) in axons and glia of the crayfish medial giant nerve fiber.
  24. Altmetric Badge
    Chapter 23 NAAG as a neurotransmitter.
  25. Altmetric Badge
    Chapter 24 Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
  26. Altmetric Badge
    Chapter 25 N-acetylaspartylglutamate (NAAG) in spinal cord injury and disease.
  27. Altmetric Badge
    Chapter 26 N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease.
  28. Altmetric Badge
    Chapter 27 Concluding Remarks
Attention for Chapter 24: Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

1 blog


27 Dimensions

Readers on

16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Chapter number 24
Book title
N -Acetylaspartate
Published in
Advances in experimental medicine and biology, June 2006
DOI 10.1007/0-387-30172-0_24
Pubmed ID
Book ISBNs
978-0-387-30171-6, 978-0-387-30172-3

Thomas AG, Wozniak KM, Tsukamoto T, Calvin D, Wu Y, Rojas C, Vornov J, Slusher BS, Ajit G. Thomas, Krystyna M. Wozniak, Takashi Tsukamoto, David Calvin, Ying Wu, Camilo Rojas, James Vornov, Barbara S. Slusher


GCP II inhibition decreases extracellular excitotoxic glutamate and increases extracellular NAAG, both of which provide neuroprotection. We have demonstrated with our potent and selective GCP II inhibitors efficacy in models of stroke, ALS and neuropathic pain. GCP II inhibition may have significant potential benefits over existing glutamate-based neuroprotection strategies. The upstream mechanism seems selective for excitotoxic induced glutamate release, as GCP II inhibitors in normal animals induced no change in basal glutamate. This suggestion has recently been corroborated by Lieberman and coworkers24 who found that both NAAG release and increase in GCP II activity appear to be induced by electrical stimulation in crayfish nerve fibers and that subsequent NAAG hydrolysis to glutamate contributes, at least in part, to subsequent NMDA receptor activation. Interestingly, even at relatively high doses of compounds, GCP II inhibition did not appear to be associated with learning/memory deficits in animals. Additionally, quantitative neurophysiological testing data and visual analog scales for 'psychedelic effects' in Phase I single dose and repeat dose studies showed GCP II inhibition to be safe and well tolerated by both healthy volunteers and diabetic patients. GCP II inhibition may represent a novel glutamate regulating strategy devoid of the side effects that have hampered the development of postsynaptic glutamate receptor antagonists.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 6%
Unknown 15 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 38%
Researcher 4 25%
Student > Ph. D. Student 2 13%
Professor > Associate Professor 1 6%
Unknown 3 19%
Readers by discipline Count As %
Agricultural and Biological Sciences 5 31%
Medicine and Dentistry 5 31%
Environmental Science 1 6%
Psychology 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Other 1 6%
Unknown 2 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2012.
All research outputs
of 3,631,265 outputs
Outputs from Advances in experimental medicine and biology
of 971 outputs
Outputs of similar age
of 275,352 outputs
Outputs of similar age from Advances in experimental medicine and biology
of 79 outputs
Altmetric has tracked 3,631,265 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 971 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,352 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.